Format

Send to

Choose Destination
Lancet Infect Dis. 2019 Sep;19(9):937-938. doi: 10.1016/S1473-3099(19)30438-4.

Dolutegravir becomes first choice for HIV.

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center